BioSpace News Archive

There’s no mistaking the typical “office jerk.” But what about some more subtle forms of negative behavior or attitudes that prove you are a jerk at work?

This week had three important target action dates, known as Prescription Drug User Fee Act (PDUFA) dates, for the U.S. Food and Drug Administration (FDA). The agency got ahead of its schedule and approved all of these drugs ahead of schedule. Let’s take a look.

Four months after acquiring GlaxoSmithKline’s rare disease gene therapy portfolio, U.K.-based Orchard Therapeutics secured $150 million in an oversubscribed Series C funding round. The funds will be used to advance three late-stage programs that it gained from the deal with GSK.

Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.

This morning Genentech announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Xolair to treat exposure to those deadly food allergies.

Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—mostly gains—at the six-month mark.

New research suggests that even thinking about or anticipating workplace communication can be harmful to your health, relationships, and overall well-being.

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is the first and only RNA interference (RNAi) therapeutic to ever be approved.

Tarrytown, N.Y.-based Regeneron received some unwelcome news. The U.S. Food and Drug Administration (FDA) rejected the company’s attempt to secure a supplemental approval for its blockbuster drug Eylea as a once-per 12-week treatment for wet age-related macular degeneration (wet AMD).

Western government agencies have been warning of an increase in cyber espionage from nefarious black hats and governments for years. The targets have typically been government and financial installations. But a new warning suggests that biotechnology could be a key target for cyber hackers.